Monogram Orthopaedics (NASDAQ:MGRM - Get Free Report) issued its quarterly earnings data on Wednesday. The company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.03, Zacks reports.
Monogram Orthopaedics Stock Up 2.2 %
Shares of Monogram Orthopaedics stock traded up $0.05 during mid-day trading on Wednesday, reaching $2.32. 42,956 shares of the stock traded hands, compared to its average volume of 142,773. The stock has a market capitalization of $79.60 million, a PE ratio of -4.94 and a beta of 1.66. The business has a 50-day moving average of $2.54 and a 200 day moving average of $2.50. Monogram Orthopaedics has a fifty-two week low of $1.53 and a fifty-two week high of $4.90.
Analysts Set New Price Targets
A number of equities research analysts recently issued reports on MGRM shares. Roth Capital raised shares of Monogram Orthopaedics to a "strong-buy" rating in a research note on Monday, December 9th. Roth Mkm started coverage on shares of Monogram Orthopaedics in a report on Monday, December 9th. They set a "buy" rating and a $4.00 price objective on the stock.
View Our Latest Analysis on Monogram Orthopaedics
About Monogram Orthopaedics
(
Get Free Report)
Monogram Orthopaedics, Inc focuses on developing a product solution architecture to enable patient-optimized orthopaedic implants. The company intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation for use in reconstructive joint replacement procedures.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Monogram Orthopaedics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Monogram Orthopaedics wasn't on the list.
While Monogram Orthopaedics currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.